Table 1

SLE disease activity during the time of paired result analysed by anti-dsDNA titre tertiles

dsDNA titre (EIA/CLIFT)Total visitsAvailable mean SLEDAI score (range) (n=490)Renal
(uPCR >0.5) at visit (%)
Low complements at visit (%)
H/H196.46 (0–16) (n=13)9 (47%)18 (95%)
H/M124.72 (0–16) (n=11)4 (33%)10 (83%)
H/L43.00 (0–6) (n=2)1 (25%)3 (75%)
M/H227.00 (0–18) (n=15)15 (68%)17 (77%)
M/M433.55 (0–16) (n=33)12 (28%)29 (67%)
M/L113.60 (0–14) (n=10)2 (18%)4 (36%)
M/N40 (0–0) (n=3)0 (0%)0 (0%)
L/H204.15 (0–14) (n=20)8 (40%)13 (65%)
L/M722.11 (0–16) (n=59)11 (15%)33 (46%)
L/L472.74 (0–14) (n=39)12 (26%)15 (32%)
L/N662.02 (0–10) (n=50)6 (9%)24 (36%)
N/H112.45 (0–6) (n=11)3 (27%)6 (55%)
N/M682.57 (0–18) (n=61)11 (16%)30 (44%)
N/L601.29 (0–10) (n=55)2 (3%)25 (42%)
N/N1271.98 (0–12) (n=108)22 (17%)48 (38%)
  • anti-dsDNA, anti-dsDNA antibodies; H, high positive; L, low positive; M, moderate positive; N, negative; SLEDAI, SLE Disease Activity Index; uPCR, urine protein to creatinine ratio.